(b) to (d) The major brands based on this drug are marketed by M/s. Ranbaxy Laboratories and Win-Medicare. The details of turnover during the last three years are not monitored. Details of prices fixed of the popular brands are being collected and would be laid on the Table of the Rajya Sabha.

(e) to (g) Imports of Dextropropoxyphene are not banned under the import policy. The process of fixing the price of the drug is at an advance stage. The details of prices fixed for each brand and their sales turnover as well as the total sales turnover of Analgesics and Antipyretics are being collected.

Re-endorsement of formulation capacity of M/s. Abbott Labs.

2241. SHRI HAYAT ULLA ANSARI: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) whether it is a fact that re-endorsement of formulation capacity was done in favour of Abbott Labs with a condition to achieve ratio parameter of bulk drugs and formulations before 17th August, 1984;

(b) if so, what was the production of bulk drugs and formulations, on 31st August, 1984 and what was the percentage between the two;

(c) whether it is a fact that in case of failing to achive the required ratio, the company is required to export the total production of formulation; and

(d) if so, what are the details of exports, indicating the names of formulations, composition, quantity of each and the country to which exported?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI VEERENDRA PATIL): (a) to (d) The information is being collected and will be laid on the Table of the House.

Production of drug by Cipla

2242. SHRI HAYAT ULLA ANSARI: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) what is the ex-factory cost of production of bulk drugs and formulations of Cipla and ratio percentage during the last three years, yearwise;

(b) whether it is a fact that Cipla is 100 per cent Indian Company and had neither imported any technology nor paid any royalty;

(c) if so, for what bulk drugs this company developed the processes either individually or with the help of Government laboratories;

(d) what is the policy in regard to ratio parameter for India company and numbers and names of bulk drugs produced by this company first in the country;

(e) whether it is also a fact that this company developed technology for production of important anticancer drugs from basic stages such as Vincrestine, Vinblastine, Futra for and the only company to produce commercially in the country; and

(f) what are the awards which the company got during the last four years in regard to exports and development of technology etc?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI VEERENDRA PATIL): (a) to (f) The information is being collected and will be laid on the Table of the House.

On-the-spot verification of unauthorised Plant and machinery of drug companies

2243. SHRI SURESH PACHOURI: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) whether the report in respect of on-the-spot verification of unautho-

rised plant and machinery installed by Glaxo, Fairdeal Corporation, German Remedies, Bayer, Pfizer, Burroughs Welcome, Hoechst, Abbott and S.G. Pharmaceuticals has been submitted by the Technical Team; if so, when each report was submitted;

(b) whether final decision has been taken on each report; if so, what are the details thereof and when the same will be laid on the table of the House;

(c) whether it is a fact that all the locations of units of each company were not inspected; if so, the reasons therefor; and

(d) what was the value of plant and mahinery proposed for each project by each company, what was the value when the team visited and what were the major plants and machinery added in the meantime?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI VEERENDRA PATIL): (a) to (d) In 1984-85, on the spot verification of installation of plant and machinery were taken up in respect of all the companies referred to in the question except M/s. German Ramedies. In the case of M/s. Fairdeal Corporation of India Limited final view was taken that there was no case of infraction of Industries (Development & Regulation) Act. The reports in other cases are being processed.

Shortage of Anti-T.B. Drug

2244. SHRI SURESH PACHOURI: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) whether B1-Teben tablets used by TB patients, manufactured by Bayer is not available in the market;

(b) what was the production of these tablets during 1979-80 and 1984-85;

(c) what is the price fixed for each pack of these tablets;

(d) whether it is a fact that the company is concentrating more on the production of non-essential items such as Bayers Tonic; Campoferron liquid, Edinol Capsules, Multibay Capsules and liquid;

(e) if so what was the sales turnover of each of these products during the last five years, year-wise, as well as that of B1-Teben tablets during the same period;

(f) what is the price fixed for each of these products and at what price each one is being sold; and

(g) what is the total sales turnover of the Company and the percentage sale of each of the vitamin preparation during the last three years, year-wise?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI VEERENDRA PATIL): (a) No, Sir. No shortage of B1-Teben tablets has been reported.

(b) Details are being collected and would be laid on the Table of the Rajya Sabha.

(c) The prices fixed for 2 packs of B1-Teben tablets are given below:—

		Rs.
B1-Teben Tabs	100's	4.97
	1000's	37.66

(d) to (g) Information to the extent available would be collected and laid on the Table of the Rajya Sabha.

Formulators of Gentamycin

2245. SHRI SYED REHMAT ALI: Will the Minister of CHMICALS AND FERTILIZERS be pleased to refer to answer to Unstarred Question 692 given in the Rajya Sabha on the 29th July, 1985 and state:

(a) names of formulators of Gentamycin to whom notices were issued and date of issuance;